Holen Sie sich die Stockscreener-App
4.89
1.03%
0.05
Handel nachbörslich:
4.89
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - Yahoo Finance
Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus
Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat
Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat
Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media
Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan
Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan
Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake - Stock Titan
Lexeo (NASDAQ: LXEO) holder plans stock sale to cover tax bill - Stock Titan
Lexeo Therapeutics (LXEO) holder plans 1,304-share sale - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares - Stock Titan
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan
Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan
Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan
Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan
Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com
META_TITLE_QUOTE - Yahoo Finance
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Lexeo Therapeutics advances gene therapy and gains RMAT status - TipRanks
LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway - TradingView
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020 - Quiver Quantitative
Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary - TradingView
Lexeo Reports $25.9 Million Q2 Net Loss as SUNRISE-FA 2 Begins - Moomoo
Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash - Stock Titan
Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics (LXEO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO) - Stock Titan
Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status - AllSci
Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday - MarketBeat
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020 - TradingView
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.com
Lexeo Therapeutics (LXEO) Advances 1.7% to $4.49, Holding Above Key SupportAI Trade Signals - dars.gov.et
Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy - Bitget
Lexeo wins FDA RMAT status for LX2020 - PharmaTimes
Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC - MarketBeat
Lexeo Therapeutics (LXEO) Pulls Back 5% as Selling Pressure IntensifiesTriple Bottom - vinanet.vn
Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Strong-Buy at Chardan Capital - MarketBeat
Lexeo Therapeutics Inc (LXEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexeo Therapeutics Inc (LXEO) Balance Sheet - TradingKey
Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexeo Therapeutics, Inc. Revenue Breakdown – NASDAQ:LXEO - TradingView
Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexeo Therapeutics Inc (LXEO) Cash Flow - TradingKey
Lexeo Therapeutics (LXEO) Slips 1.82% as Stock Tests Support Near $4.35Profitability Factor - dars.gov.et
Lexeo Therapeutics Inc (LXEO) Income Statement - TradingKey
LXEO|Lexeo Therapeutics Inc|Price:4.660|Chg%:-0.050 - TradingKey
Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Affinity Asset Advisors LLC Increases Stock Position in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
LXEO|Lexeo Therapeutics Inc|Price:4.925|Chg%:-0.055 - TradingKey
Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor Focus - TipRanks
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):